Patients with anti-PM-Scl-75 also had more frequent SSc-ILD than those negative for this reactivity, whereas anti-PM-Scl-100 correlated with the rarer occurrence of the dcSSc subset, confirming the findings of a study by Wodkowski et al., who found that anti-PM-Scl-75 patients had better survival than other antibody subsets [52]. This evidence concerns the gene EXOSC10 and interstitial lung disease.